TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 421726

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Procyclidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lactose dummy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Television pupillometry
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional autonomic function tests
Number of subjects: 8
Study: 31897661

Group type: EXPERIMENTAL
Intervention: Oregovomab combined with standard-of-care (SOC) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oregovomab combined with SOC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline immune environment
Number of subjects: 0
Study: 30565996

Group type: EXPERIMENTAL
Intervention: Very early invasive evaluation (ICA within 12 hours)
Number of subjects: 2147

Group type: COMPARATOR
Intervention: Standard invasive care (ICA within 48 to 72 hours)
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Very early invasive evaluation (ICA within 12 hours) among patients with GRACE risk score >140
Number of subjects: 2147

Group type: COMPARATOR
Intervention: Standard invasive care (ICA within 48 to 72 hours) among patients with GRACE risk score >140
Number of subjects: 2147
Study: 25567069

Group type: EXPERIMENTAL
Intervention: Brazil nuts (288.75 µg/day) for 6 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no Brazil nuts)
Number of subjects: 31
Study: 25354738

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 22929242

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control tissue
Number of subjects: 24
Study: 20813339

Group type: EXPERIMENTAL
Intervention: aMCI patients fulfilling biomarker criteria (CSF Aβ1‐42 ≤192 mg/mL or total‐tau/Aβ1‐42 >0.39)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo group (aMCI patients not requiring biomarker criteria)
Number of subjects: 400
Study: 17683300

Group type: EXPERIMENTAL
Intervention: EBM educational intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study: 16275831

Group type: EXPERIMENTAL
Intervention: BoNTA
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: BoNTB
Number of subjects: 139
Study: 12145593

Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg intravenously over 30 minutes)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 41
Study: 10673879

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg i.v.
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Cyclizine vs Ondansetron (for diagnostic laparoscopy)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ondansetron vs Cyclizine (for laparoscopic sterilization)
Number of subjects: 175
Study: 7562882

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day before breakfast) for 4 and 8 weeks
Number of subjects: 30
Study: 1834827

Group type: EXPERIMENTAL
Intervention: Intravenous administration of teicoplanin (6 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of teicoplanin (6 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (administered by the other route)
Number of subjects: 24
Study: 7032534

Group type: EXPERIMENTAL
Intervention: plafibride
Number of subjects: 0

Group type: COMPARATOR
Intervention: clofibrate
Number of subjects: 0
Study: 30948242

Group type: EXPERIMENTAL
Intervention: Kinesia 360 (Experimental Group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 39
Study: 26308904

Group type: EXPERIMENTAL
Intervention: Loss-framed message for high sensation seekers
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Gain-framed message for low sensation seekers
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Message frame fit with viewer's way of thinking
Number of subjects: 504
Study: 24000163

Group type: EXPERIMENTAL
Intervention: e-diary (handheld touch screen device)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: electronically read diary (card with predefined slots)
Number of subjects: 22

Group type: COMPARATOR
Intervention: standard paper diary
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: electronic report
Number of subjects: 22
Study: 22371069

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered at 6 and 12 months (Group 1)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered at 12 and 18 months (Group 2)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered at 15 and 21 months (Group 3)
Number of subjects: 197
Study: 20205331

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17627198

Group type: COMPARATOR
Intervention: Healing Touch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined intervention (Healing Touch + Coaching)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 0
Study: 16339094

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 762

Group type: COMPARATOR
Intervention: Allopurinol 300 mg
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Febuxostat (combined groups)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Allopurinol group
Number of subjects: 762
Study: 12177641

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/control
Number of subjects: 0
Study: 9883098

Group type: EXPERIMENTAL
Intervention: Alcohol + Frustration group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 42
Study: 8267692

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg OD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3715789

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin formulations (300-650 mg)
Number of subjects: 6
Study: 31414571

Group type: EXPERIMENTAL
Intervention: Personality disorder
Number of subjects: 201

Group type: COMPARATOR
Intervention: No personality disorder
Number of subjects: 201

Group type: COMPARATOR
Intervention: General population
Number of subjects: 201
Study: 29329996

Group type: EXPERIMENTAL
Intervention: Antiflatulent medication
Number of subjects: 78

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 78
Study: 26803422

Group type: EXPERIMENTAL
Intervention: Intraprocedural stent thrombosis (IPST)
Number of subjects: 6591

Group type: EXPERIMENTAL
Intervention: No-reflow/slow reflow
Number of subjects: 6591

Group type: EXPERIMENTAL
Intervention: New/worsened thrombus
Number of subjects: 6591

Group type: EXPERIMENTAL
Intervention: Distal embolization
Number of subjects: 6591

Group type: EXPERIMENTAL
Intervention: Abrupt closure
Number of subjects: 6591
Study: 24673048

Group type: EXPERIMENTAL
Intervention: Warm acupuncture therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Electroacupuncture therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medication therapy
Number of subjects: 90
Study: 22153972

Group type: EXPERIMENTAL
Intervention: Pramipexole (4.25±0.38 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20514506

Group type: EXPERIMENTAL
Intervention: Pelvic autonomic nerve preservation during rectal cancer surgery
Number of subjects: 17
Study: 17680204

Group type: EXPERIMENTAL
Intervention: Preoperative epidural fentanyl 100 microg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (without preoperative epidural fentanyl)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received continuous infusion of fentanyl 30 microg x ml(‐1) and 2 mg/ml bupivacaine at a rate of 0.7 ml x h(‐1) for 72 h postoperatively
Number of subjects: 40
Study: 16260983

Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16
Study: 11889009

Group type: EXPERIMENTAL
Intervention: NTG group (48 hours of continuous NTG infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nitrate therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NTG group
Number of subjects: 0
Study: 10461554

Group type: EXPERIMENTAL
Intervention: High speed ambulance transport
Number of subjects: 54

Group type: COMPARATOR
Intervention: Smooth ambulance transport
Number of subjects: 54
Study: 7502428

Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg once daily
Number of subjects: 486

Group type: COMPARATOR
Intervention: Castration (surgical or medical)
Number of subjects: 486
Study: 2038931

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topical lidocaine (3 mg/kg)
Number of subjects: 24
Study: 7227966

Group type: EXPERIMENTAL
Intervention: Hospitalization for patients with uncomplicated acute myocardial infarction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home care with patient monitoring for two hours by a team of technicians dispatched with a specially equipped ambulance
Number of subjects: 0
Study: 31078094

Group type: EXPERIMENTAL
Intervention: Integrated Intervention Program for Alcoholism (IIPA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 50
Study: 27544517

Group type: EXPERIMENTAL
Intervention: PATH+ Intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) Control
Number of subjects: 238
Study: 25831269

Group type: EXPERIMENTAL
Intervention: Direct SMS message indicating abnormal results and requesting return to clinic
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: PIN-protected SMS message
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Coded SMS message ('ABCDEFG')
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Normal SMS message indicating results were normal
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: All SMS formats (direct, PIN, coded) for abnormal results
Number of subjects: 385
Study: 24103380

Group type: EXPERIMENTAL
Intervention: High n-3 long-chain polyunsaturated fatty acid (LCPUFA) intake
Number of subjects: 2378
Study: 21462240

Group type: EXPERIMENTAL
Intervention: Trospium chloride 60 mg XR once daily
Number of subjects: 1027
Study: 19214891

Group type: EXPERIMENTAL
Intervention: Endocytoscopy (ECS)
Number of subjects: 41
Study: 17255844

Group type: EXPERIMENTAL
Intervention: Small volume enemas
Number of subjects: 81

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 81
Study: 15514344

Group type: EXPERIMENTAL
Intervention: Multifaceted collaborative quality improvement intervention
Number of subjects: 6039

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 6039
Study: 11389399

Group type: EXPERIMENTAL
Intervention: Postural hygiene program (11 sessions)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (placebo + no intervention)
Number of subjects: 106
Study: 9771983

Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imaging
Number of subjects: 4

Group type: COMPARATOR
Intervention: TRUE Test patch test (0.20 mg/cm2 for 48 h)
Number of subjects: 4
Study: 8946630

Group type: EXPERIMENTAL
Intervention: Syva MicroTrak EIA
Number of subjects: 328

Group type: COMPARATOR
Intervention: Syva Direct Specimen Test
Number of subjects: 328
Study: 2667388

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine 0.5%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hyperbaric cinchocaine 0.5%
Number of subjects: 90
Study: 1004355

Group type: EXPERIMENTAL
Intervention: Molsidomine 2 mg (sublingual or enteral)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Isosorbiddinitrate 20 mg (sublingual)
Number of subjects: 43
Study: 31996605

Group type: EXPERIMENTAL
Intervention: Telehealth social communication skills training (TBIconneCT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: In-person social communication skills training
Number of subjects: 51

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 51
Study: 31706329

Group type: EXPERIMENTAL
Intervention: Patient-targeted intervention (video and prompt card)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Provider-targeted intervention (encounter decision aids and training)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 29
Study: 29140840

Group type: EXPERIMENTAL
Intervention: High-Voltage Electrical Stimulation (HVES) applied for 60 minutes 3 times per week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ultrasound (US) applied 3 times per week
Number of subjects: 27
Study: 24849310

Group type: EXPERIMENTAL
Intervention: Vitamin E (VitE)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 23701973

Group type: EXPERIMENTAL
Intervention: Complex Ayurvedic treatment including tailored combinations of manual treatments, massages, dietary and lifestyle advice, nutritional supplements, yoga posture advice, and knee massage.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional standard care including self-care advice, pain medication, weight-loss advice (if overweight), and physiotherapy following current international guidelines.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Complex Ayurvedic treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional standard care
Number of subjects: 150
Study: 22028817

Group type: EXPERIMENTAL
Intervention: Water Guard (sodium hypochlorite solution)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate tablets (Aquatabs)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combined flocculant-disinfectant powdered mixture (PUR Purifier of Water)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Silver-coated ceramic siphon filter
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (200 households)
Number of subjects: 600
Study: 19019624

Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA 100 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (ASA 100 mg/d + C 75 mg/d)
Number of subjects: 60
Study: 17381572

Group type: EXPERIMENTAL
Intervention: Mapleson D breathing system
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mapleson F breathing system
Number of subjects: 14

Group type: COMPARATOR
Intervention: TSAA
Number of subjects: 14
Study: 15486749

Group type: EXPERIMENTAL
Intervention: Packing of perianal abscess cavity
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonpacking of perianal abscess cavity
Number of subjects: 50
Study: 12575571

Group type: EXPERIMENTAL
Intervention: Yinfu Decoction (YFD) combined with transfer factor
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 35
Study: 9847433

Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT)
Number of subjects: 8
Study: 8164932

Group type: EXPERIMENTAL
Intervention: 200 micrograms misoprostol
Number of subjects: 100
Study: 3310722

Group type: EXPERIMENTAL
Intervention: Controlled release morphine tablets (twice daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aqueous morphine sulphate (4-hourly)
Number of subjects: 27
Study: 31469027

Group type: EXPERIMENTAL
Intervention: Phytic acid drink
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 48
Study: 29738277

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 28560947

Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 2148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2148
Study: 25742614

Group type: EXPERIMENTAL
Intervention: Group Audiological Rehabilitation (GAR) program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 24
Study: 24074707

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFNa-2a) for 48 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Entecavir (ETV) continued therapy
Number of subjects: 57
Study: 21877028

Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 44
Study: 18777192

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 34614

Group type: COMPARATOR
Intervention: Standard Chest X-ray (CXR)
Number of subjects: 34614
Study: 16319906

Group type: EXPERIMENTAL
Intervention: valsartan (160 mg)
Number of subjects: 24
Study: 15478553

Group type: EXPERIMENTAL
Intervention: Artificial pneumothorax (AP) during chemotherapy with reserve drugs
Number of subjects: 43

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 43
Study: 11014757

Group type: EXPERIMENTAL
Intervention: Fire Ensemble (FE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sports Ensemble (SE)
Number of subjects: 18
Study: 9115056

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 12
Study: 1343270

Group type: EXPERIMENTAL
Intervention: Combination therapy, ACE inhibitors, methyldopa
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vasodilators (minoxidil, hydralazine)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 104
Study: 3909336

Group type: EXPERIMENTAL
Intervention: Single 1-g intramuscular dose of aztreonam for acute uncomplicated cystitis
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Multiple parenteral doses of aztreonam (usually a five-day course of 1 g two or three times daily)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Multiple-dose therapy of aztreonam
Number of subjects: 681

Group type: COMPARATOR
Intervention: Aztreonam
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Multiple-dose therapy of aztreonam in patients with multiply drug-resistant bacteria
Number of subjects: 681
Study: 31729087

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (Net-En)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Copper intrauterine device (CU-IUD)
Number of subjects: 98
Study: 30665436

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) plus probiotic (8 x 10^9 CFU/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitamin D and probiotic co-supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29553453

Group type: EXPERIMENTAL
Intervention: UNRWA health centre services for non-communicable diseases
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: General impressions, accessibility, communication, interpersonal relationships
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Technical quality of services, clinic environment, convenience of services
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Demographic factors (unmarried, working, living in southern Gaza, educated, received educational materials)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Specific health provider, receiving all medications from UNRWA, not turned away from clinic
Number of subjects: 400

Group type: COMPARATOR
Intervention: Sex, age, presence of disability, presence of complications, control status, kind of non-communicable disease, type of treatment provided, duration of non-communicable disease
Number of subjects: 400
Study: 27735912

Group type: EXPERIMENTAL
Intervention: Ticagrelor + ASA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel + ASA
Number of subjects: 0
Study: 24508026

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly for 6 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23049758

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19296845

Group type: EXPERIMENTAL
Intervention: Fermented dairy product containing Bifidobacterium lactis DN-173 010
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control product (acidified milk without ferments, toilet training, bowel diary)
Number of subjects: 160
Study: 17671933

Group type: EXPERIMENTAL
Intervention: Small pupil group (pupil size of 2.5-2.9 mm; 45 subjects)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Large pupil group (pupil size of 3-5 mm; 17 subjects)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Small pupil group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 62
Study: 15233669

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 135 microg/wk
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 180 microg/wk
Number of subjects: 639

Group type: COMPARATOR
Intervention: interferon alpha‐2a 3 MIU thrice weekly
Number of subjects: 639
Study: 11581479

Group type: EXPERIMENTAL
Intervention: Single-use sterile catheters
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reuse of clean catheters
Number of subjects: 10
Study: 9572829

Group type: EXPERIMENTAL
Intervention: Iron supplement (135 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 8083793

Group type: EXPERIMENTAL
Intervention: Comprehensive oral hygiene training program (3.5 hours per child)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Less comprehensive oral hygiene training program (1.5 hours per child)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (no preventive program)
Number of subjects: 227